Sino Biopharmaceutical (01177.HK) Rises Over 5% on Strategic Acquisition of siRNA Firm Hejiya to Accelerate Chronic Disease Pipeline

According to the Zhisheng Finance APP, Sino Biopharm (01177) rose more than 5% again, and as of press time, it increased by 4.92%, trading at HK$7.24, with a turnover of HK$303 million.

In terms of news, Sino Biopharmaceutical Co., Ltd. announced that on January 13, 2026, the company (through the buyer) fully acquired Hygieia. The buyer, Zhengda Pharmaceutical Investment (Beijing) Co., Ltd. (a wholly-owned subsidiary of the company), entered into a sale and purchase agreement with the sellers (collectively referred to as the existing shareholders of Hygieia as of the date of the sale and purchase agreement), the founders (Kunyuan Cui and Tao Guan), Hygieia, Guangzhou Subsidiary (Guangzhou Hygieia Biomedical Technology Co., Ltd.), Xiamen Subsidiary (Xiamen Ganbaoli Biomedical Co., Ltd.), and Shanghai Subsidiary (Shanghai Heyi'an Biomedical Co., Ltd.).

Pursuant to the Sale and Purchase Agreement, the Seller has conditionally agreed to sell and the Buyer has conditionally agreed to purchase 100% of the equity interest in Hygieia, at a maximum base consideration of RMB 12 million (subject to adjustment), which will be paid partly in cash and partly in consideration shares. Upon completion, Hygieia will become an indirect wholly-owned subsidiary of the Company.

Hygieia is a pioneering biopharmaceutical company focused on the research and development of innovative small interfering RNA (siRNA) drugs. It has established an integrated innovative drug development system from target discovery to clinical proof-of-concept (POC), with a primary focus on three major chronic disease areas: weight management and metabolism, cardiovascular and cerebrovascular diseases, and the nervous system. This forward-looking strategic acquisition will accelerate the group's innovative layout and clinical advancement in the field of chronic diseases, leading the way for next-generation innovative therapies to benefit patients worldwide.

Hygieia has successfully developed a differentiated delivery platform covering multiple tissues, with independent intellectual property rights. Its core platform MVIP (Multi-Valent Import Platform) is the world's first clinically validated liver-targeted delivery platform capable of achieving ultra-long-acting "once-a-year" dosing, addressing the most challenging compliance issues in chronic disease treatment.